Fresh from the biotech pipeline-2012.

The article offers information on the approval of several new drugs by the U.S. Food and Drug Administration (FDA). It states that the therapies granted orphan drug status because they address rare diseases which make up to 32 percent of the new drug approvals. Table listing several drugs including Ducord, Gintuit and Raxibacumab is also presented.